Author

Michael F Berger

h-index 1 View on Semantic Scholar

We have 1 of 2 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Aug 2026

Irradiated CD19 chimeric antigen receptor YTS cells retain antitumor activity and offer a scalable alternative to autologous CAR-T therapy.

E engineered YTS cells are positioned as a novel, scalable, and cost-effective "off-the-shelf" immunotherapy platform suitable for treating refractory leukemias and lymphomas and future studies will be required to assess safety and to explore applicability to autoimmune diseases and solid tumors.

Hanan Jaber, Anas Abu Khalaf, L. Weiss et al. · Haematologica · 0 citations